Another Alzheimer’s breakthrough on its way?
The World Health Organization (WHO) recommends that “proactive management of modifiable risk factors can delay or slow the onset or progression of the disease” and stresses the importance of early intervention.
David A. Merrill, MD, PhD, Sarah C. McEwen, PhD will together with 16 other experts explore the effectiveness of a 12-month data-driven lifestyle recommendation program in a randomized controlled trial (RCT) designed to target multiple systematic pathways implicated in AD.
It will be the first published study to examine the efficacy of a personalized, multimodal intervention in individuals with MCI or early AD and confirmed AD neuropathology.
They will among others examine effects on cognition and hippocampal volume by using the #Neuroreader® software.
Overall goal: To longitudinally track biological systems implicated in AD to reveal the dynamics between these systems during the intervention to understand differences in treatment response.
Read the complete article by clicking here